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Development of a tumour-specific drug delivery system is challenging and depends 
immensely on the carrier. Currently various approaches are considered to develop 
efficient drug delivery systems.1,2  Leaky vasculature, associated with sustained tumour 
angiogenesis together with tumour-associated poor lymphatic drainage can enhance 
passive targeting of nano-particles (NPs) to malignant tissue resulting in the enhanced 
permeability retention effect.3,4 Nanoparticulate drug formulations, exploiting this 
feature of the tumour microenvironment, can be used to deliver chemotherapeutic 
agents to tumour target sites thereby increasing the therapeutic effect while minimising 
systemic toxicities.5 When selecting a delivery system a major consideration is 
controlled release of the drug to the target site at a therapeutically optimal rate.1,6 
 Human ferritin is an ideal drug delivery carrier due to the nanoscale structure, and 
biocompatible, biodegradable, stable, non-toxic properties.2,7,8 Ferritin consists of an 
apoferritin (AFt) protein cage and an iron core, and prevents accumulation of toxic 
levels of free iron in cells. AFt is composed of 24 subunits arranged into a 12 nm 
diameter cage with an internal 8 nm cavity. AFt is comprised of heavy (H) and light 
(L) chains which are highly homologous but functionally distinct. The AFt cage has 14 
channels, each 3-4 Å in diameter, to allow exchange of cargo between the protein cage 
interior and exterior environments. Among the 14 channels, 8 are hydrophilic and 6 are 
hydrophobic.6,7,9 Also, the AFt cage can disassemble into subunits at low pH (< pH 
4.0) allowing release of cargo, and reassemble at higher pH (> pH 5.0).5 Ferritin 
circulates and binds to a variety of cell types, however, specific binding to cells has 
been seen only for H-ferritins.10 Ferritin binding sites and endocytosis of ferritin have 
been found in neoplastic cells,11 and were associated with membrane specific 
transferrin receptors (TfR) that are highly expressed in many cancers12 including breast 
and brain cancer cells.12,13 The unique architecture of AFt provides two interfaces: the 
outer surface of AFt can be modified chemically or genetically with functional motifs14 
 1  2  3  4  5  6  7  8  9 1011121314151617181920212223242526272829303132333435363738394041424344454647484950515253545556575859606162636465
3  
and the internal cavity can be used to encapsulate pharmaceutical agents such as anti-
cancer drugs, MRI and fluorescent imaging agents.6,9,15,16 Recently, selective targeting 
and cargo delivery with H-AFt was demonstrated both in vitro17 and in vivo.18  
 
(EGFR) tyrosine kinase inhibitor.19 This receptor family comprises four homologous 
receptors: EGFR (ErbB1/HER1), HER2 (ErbB2), HER3 (ErbB3) and HER4 (ErbB4), 
which have an extracellular ligand binding domain, a single hydrophobic trans-
membrane domain and a cytoplasmic tyrosine kinase domain. These receptors are 
activated by either homo- or hetero-dimerisation upon ligand binding resulting in 
phosphorylation of specific tyrosine residues.20,21 The overexpression of EGFR and 
HER2 in breast cancer, is associated with poor prognoses.20,22,23 Gefitinib is used for 
treatment of EGFR and HER2 overexpressing breast cancers.24,25 However, the 
therapeutic window of this drug is drastically narrowed by poor bioavailability, 
acquired resistance due to insufficient or ineffective cellular uptake and systemic 
toxicity resulting from interactions between drug and healthy tissue.19,26 Also, orally 
administered Gefitinib is taken up extensively by human serum albumin and hence 
other delivery systems such as liposomes have been investigated.27 Development of a 
selective targeted delivery system would improve efficiency of Gefitinib treatment.  
 Herein we report the use of human heavy chain apoferritin (H-AFt) as a delivery 
cage for Gefitinib to improve drug selectivity for HER2 overexpressing cells. The H-
AFt-encapsulated-Gefitinib (H-AFt/Gefitinib) nanocomposite has potent and enhanced 
anti-tumour activity against the HER2 overexpressing SKBR3 breast cancer cell line 
(GI50 = 0.52 50 = 1.66 ; Table 1). Enhanced 
drug efficacy is achieved through sustained controlled drug release from the H-AFt 
cavity. In contrast, H-AFt-encapsulated-Gefitinib treatment of MDA-MB-231 breast 
cancer cell line, which does not express HER2, has shown decreased uptake of 
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Gefitinib compared to treatment with un-encapsulated drug. These results expose 
prospects for utilisation of H-AFt as a carrier for targeted delivery of anti-cancer drugs 
to HER2 over-expressing tumours.  
 For efficient entrapment of any drug into a delivery system, consideration of 
physical properties of both the drug and delivery system is important. Gefitinib is a 
hydrophobic drug and H-AFt has 6 hydrophobic channels allowing the drug molecules 
to enter the H-AFt cavity by passive diffusion during mixing of the drug with the 
protein (Figure 1a).28 Gefitinib has low solubility in aqueous buffers29 and was first 
dissolved in DMSO and then diluted with PBS at pH 7.2. This 1 mM aqueous solution 
of Gefitinib was mixed with H-AFt. The lateral dimensions of Gefitinib are < 0.3 nm, 
allowing Gefitinib intake through 6 hydrophobic channels by diffusion. The resulting 
solution was exhaustively dialysed and centrifuged at high speed to remove any un-
encapsulated Gefitinib and any impurities. The encapsulation of Gefitinib was 
confirmed by UV spectrophotoscopy. Absorbance of Gefitinib was analysed at 250 nm 
and the encapsulation efficiency (EE) was quantified according to the Beer-Lambert 
law to be ~ 55%. 
 Mass spectrometry measures the mass to charge ratio and can be used to determine 
the purity and the molar mass of the particles.30 Matrix-enriched laser desorption 
ionisation (MALDI) studies revealed high intensity peaks for H-AFt and Gefitinib 
which indicates high abundance of the drug and the protein in the mixture 
corresponding to a H-AFt molecular weight (MW) of 24.71 kDa and Gefitinib MW of 
442.6 Da, comparable to the expected values (Supporting Information, S1). Protein 
determination by Bradford assay revealed 1.25 mg H-AFt/ml  equivalent to 50.6 µM. 
UV spectrophotometry determined a ratio of 605 µM Gefitinib / 50.6 µM H-AFt 
indicating > 10 molecules of Gefitinib per H-AFt cavity. Further evidence of Gefitinib 
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encapsulation within H-AFt was provided by flow cytometry analysis (Supporting 
Information, S1). 
 The stability and the structural integrity of H-AFt-encapsulated-Gefitinib were 
confirmed by PAGE and TEM. PAGE profile of H-AFt-encapsulated-Gefitinib 
revealed a band similar to that of H-AFt only, at MW ~ 24.7 kDa (Figure 1b). This 
indicates that the AFt protein structure and charge remain unchanged after 
encapsulation of Gefitinib. TEM images (Figure 1c) show intact H-AFt shells with an 
outer diameter of 13  1 nm, and confirm that the H-AFt-encapsulated-Gefitinib retains 
the spherical shape and the size expected for H-AFt. The electron density of Gefitinib 
molecules is similar to that of H-AFt, hence there was insufficient contrast to resolve 
encapsulated Gefitinib in TEM. 
 In vitro effects of H-AFt-encapsulated-Gefitinib were assessed using the HER2 
over-expressing SKBR3 cell line that expresses low levels of EGFR. As a negative 
control MDA-MB-231 cell line was used which does not express HER2 but expresses 
high levels of EGFR.24 
 Cellular internalisation of H-AFt-encapsulated-Gefitinib was observed by confocal 
microscopy and compared to that of Gefitinib. SKBR3 and MDA-MB-231 cells were 
treated with H-AFt-encapsulated-Gefitinib, Gefitinib and H-
(Figure 2 and Supporting Information, S2). The fluorescence of Gefitinib is 
environmentally sensitive: peak excitation and emission depends upon environment 
polarity and is intense in nonpolar solvents.31 This property has allowed cellular uptake 
and distribution studies to be performed. Intracellular Gefitinib was evident from the 
bright fluorescence observed within the cytoplasm of SKBR3 cells treated with H-AFt-
encapsulated-Gefitinib. Cytoplasmic Gefitinib fluorescence was punctuate consistent 
with localisation in acidic lysosomes and endosomes within these cells.31 SKBR3 cells 
treated with H-AFt alone appeared to be identical to control cells and did not show 
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fluorescence. Also MDA-MB-231 cells treated with H-AFt-encapsulated-Gefitinib did 
not show bright fluorescence compared to MDA-MB-231 cells treated with Gefitinib 
indicating uptake suppression. 
 The cellular uptake of H-AFt-encapsulated-Gefitinib was quantified using flow 
cytometry. SKBR3 and MDA-MB-231 cells were treated with H-AFt-encapsulated-
Gefitinib or Gefitinib 
used as a measure of Gefitinib uptake by the cells (Figure 1d). Significant uptake by 
SKBR3 and MDA-MB-231 cells were measured for Gefitinib. Uptake of H-AFt-
encapsulated-Gefitinib by SKBR3 cells was also significant; however uptake of H-
AFt-encapsulated-Gefitinib by MDA-MB-231 cells was not significant compared to 
control. Thus, qualitative observations of confocal microscopy were corroborated by 
flow cytometry analyses, and demonstrate successful internalisation of H-AFt-
encapsulated-Gefitinib by HER2 over-expressing SKBR3 cells. 
 In order to study in vitro anti-tumour activity of H-AFt-encapsulated-Gefitinib, cells were 
incubated with H-AFt-encapsulated-Gefitinib, Gefitinib and H-AFt for 72 h and 
growth inhibition was determined by MTT assay (Table 1; Figure 3a-b and 
Supporting Information, S3). Interestingly, the SKBR3 cell line was sensitive to both 
Gefitinib (GI50 = 0.94 ± 0.49 H-AFt-encapsulated-Gefitinib (GI50 = 1.44 ± 
0.49  However, the reduced potency of H-AFt-encapsulated-Gefitinib compared 
to Gefitinib alone implies that encapsulated Gefitinib may require time to be released 
from the H-AFt cavity as it is processed by endosome and lysosome systems with a 
local pH gradually reducing.31 Conversely the MDA-MB-231 cell line demonstrated 
significantly reduced sensitivity to both Gefitinib (GI50 = 21.80 ± 0.52 H-AFt-
encapsulated-Gefitinib (GI50 > 25  
 Although Gefitinib is an EGFR tyrosine kinase inhibitor, no correlation was 
observed between EGFR expression and sensitivity of cells. Gefitinib activity requires 
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a phosphorylated (active) form of EGFR whereas MDA-MB-231 cells express non-
phosphorylated EGFR and hence are not sensitive to this drug.24 On the other hand, 
cancer cells that express low levels of EGFR together with overexpression of HER2 
are sensitive to this drug and indeed, high sensitivity of SKBR3 cells to Gefitinib was 
observed.24,25 HER2 remains the preferred dimerisation partner of other ErbB 
receptors. Although both homo- and hetero-dimerisation activate the EGFR network, 
heterodimers are found to be more potently mitogenic and HER2 heterodimers 
generate the strongest biological activity compared to other heterodimers.20,24,32  
 
  TfR1 is associated with uptake of H-AFt and is more highly expressed in cancer 
cells compared to normal human cells.12 It has been found that the expression of TfR1 
correlates with tumour stage or cancer progression.4 Iron is required by many cellular 
processes such as metabolism and DNA synthesis. TfR1 resides on cell membranes 
and imports cargo by receptor mediated endocytosis via clathrin-coated pits.4,8 Both 
SKBR3 and MDA-MB-231 cells possess high levels of TfR133 which would assist 
cellular uptake of H-AFt-encapsulated-Gefitinib.34 The greater SKBR3 growth 
inhibition by H-AFt compared to MDA-MB-231 implies greater sequestration of H-
AFt by SKBR3 cells. Indeed, it has been shown previously that ferritin was not taken 
up by MDA-MB-231 cells.35 In this study, the enhanced activity of H-AFt-
encapsulated-Gefitinib in HER2 overexpressing cells is also a consequence of 
Gefitinib inhibition of kinase activity and therefor EGFR signalling triggered by 
HER2-EGFR dimerisation. 
 To determine whether a longer exposure time to encapsulated drug would be more 
effective in cells, MTT assays were performed following 120 h treatment (Table 1, 
Figure 3c-d). Again the SKBR3 cell line showed greater sensitivity to H-AFt alone 
compared to MDA-MB-231 cells. Interestingly the GI50 value for H-AFt-encapsulated-
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Gefitinib (0.52 ± 0.17 ) against the SKBR3 cell line was lower compared to the 72 
h assay (GI50 = 1.44 ± 0.49  (  3-fold) than that of Gefitinib 
after 120 h exposure (GI50 = 1.66 ± 0.79 ). No significant difference was found 
between the GI50 values of Gefitinib alone at 72 and 120 h. It should be noted that at 
H-AFt-encapsulated-Gefitinib GI50 values of 1.44 M and 0.52 M, equivalent 
concentrations of AFt were 0.11 M and 0.04 M respectively, concentrations which 
negligibly impact SKBR3 cellular proliferation. Consistent with results following 72 h 
exposure, after 120 h exposure, the MDA-MB-231 cell line did not show sensitivity to 
H-AFt-encapsulated-Gefitinib, GI50 > 25 µM (equivalent to 2.1 M AFt).  
 These results demonstrate that drug encapsulation enhances Gefitinib activity in 
SKBR3 cells and support the hypothesis that the H-AFt cage allows controlled release 
of drug molecules.  
 Tumour microenvironments exhibit lower extracellular pH than normal tissues 
while the intracellular pH of cells within normal and tumour cells is similar.5 The 
overall pH range within a tumour environment is 6.5-7.2 where as normal cells possess 
a pH range of 7.2-7.4, allowing pH controlled release.36 Further, the pH-dependent 
release of cargo could offer additional advantage for applications in stomach cancers, 
where an acidic environment would enhance drug release from the AFt cavity. Hence it 
was examined whether a more acidic in vitro environment would promote effective 
release of Gefitinib from its H-AFt cage. The investigations indicated that SKBR3 cells 
were unable to withstand pH < 7.0 environments for more than 72 h. However, at pH = 
7.0, H-AFt-encapsulated-Gefitinib inhibited SKBR3 cell growth in a dose-dependent 
manner following 72 h exposure (GI50 = 0.44 ± 0.16 µM), exhibiting > 3-fold 
enhanced potency, compared to pH 7.5. Clonogenic assays were performed to 
determine whether individual SKBR3 cells were able to survive challenge with 
 1  2  3  4  5  6  7  8  9 1011121314151617181920212223242526272829303132333435363738394041424344454647484950515253545556575859606162636465
9  
Gefitinib or H-AFt-encapsulated-Gefitinib and subsequently form progeny colonies, 
indicative of tumour repopulation.37 After 24 h exposure to agents followed by 13 days 
incubation with medium alone, H-AFt-encapsulated-Gefitinib demonstrated lower 
potency than Gefitinib (Figure 4). The survival fraction (SF) of cells treated with 
Gefitinib was 50.7 ± 1.5% (1  
SF of cells treated with H-AFt-encapsulated-Gefitinib was 71.8 ± 0.5% (1 
34.4% ± 5.2% (5 14 days continuous exposure to both 
agents, no colonies could be detected. These results endorse the premise of sustained 
drug release from H-AFt as an efficient drug delivery system. 
 Release of Gefitinib from H-AFt into buffer was examined at pH 2, 4 and 7.5 over a 
period of 24 h by analysing both the buffer and the solution retained within the dialysis 
bags. UV spectrometry was adopted to compare Gefitinib release from H-AFt. At pH 2 
the AFt cage completely disassembles, at pH 4 the AFt cage swells, separating the 
protein sub-units and at pH 7.5 the AFt cage retains its assembled structure.5 Rapid, 
cumulative diffusion of Gefitinib alone was observed at pH 7.5, reaching a plateau at 6 
h. In comparison, at pH 2, 4 and 7.5, detection of Gefitinib released from H-AFt-
encapsulated-Gefitinib indicates a slower cumulative release profile; progressively 
reduced drug was released from the AFt cage as pH increases (Supporting Information, 
S4). The most rapid cumulative release profile was observed at pH 2, consistent with 
the AFt cage disassembling and allowing Gefitinib release.  
 Analysis of residual buffer by flow cytometry (Supporting Information, S4) revealed 
only 2 negative populations at pH 2 and 4, exposing very low total fluorescence in the 
histograms relative to control. This implies that negligible amounts of Gefitinib were 
retained in the dialysis bags; after 24 h. However at pH 7.5, a small population positive 
for fluorescence was observed; indicating that some drug molecules remained 
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encapsulated, confirming sustained release of Gefitinib from H-AFt at physiological 
pH levels.36 
 The in vitro results indicate encapsulation of Gefitinib within an H-AFt cage could 
provide a facile route to targeted drug delivery and release in vivo. Recognition of H-
AFt by TfR1 of cancer cells allows encapsulated cargo to be selectively internalised 
into cancer cells via TfR1 mediated endocytosis3,4 and has successfully been utilised 
for targeted delivery of e.g. MRI imaging agents.38 Although angiogenesis is enhanced 
in cancers39 suggesting potential competition between endogenous ferritins and H-AFt 
uptake, a recent study demonstrated successful delivery of doxorubicin encapsulated in 
H-AFt to tumour sites and in vivo efficacy.18 Thus we envisage that the observed 
selective targeting and enhanced efficacy could be translated in vivo and merits further 
detailed studies.  
 In conclusion successful encapsulation of Gefitinib within the H-AFt cavity, 
sustained release of cargo and subsequent anti-tumour activity selectively in HER2 
overexpressing breast carcinoma cells is shown. Utilising the fluorescent property of 
Gefitinib it was able to confirm intracellular localisation of H-AFt-encapsulated-
Gefitinib in SKBR3 cells. Potent, dose-dependent growth inhibition of cancer cells 
sensitive to EGFR inhibition was achieved and clonogenic assays further provided 
evidence of sustained Gefitinib release and significant in vitro anti-cancer activity of 
H-AFt-encapsulated-Gefitinib. H-AFt encapsulation could reduce off target toxicities 
of Gefitinib and diminish drug deposition in normal tissues. AFt encapsulation 
enhances the therapeutic efficacy of Gefitinib through passive targeted delivery and 
sustained release to tumour sites which demonstrates a successful nano-scale drug 
delivery system.  
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Experimental Section  
Preparation and characterisation of H-AFt-encapsulated-Gefitinib: Gefitinib (Cayman 
Chemical USA) was dissolved in DMSO:PBS (1:1 at pH 7.2) at a concentration of 1 mM. 160 
-AFt expressed in E. coli was provided by Prof. N. R. Thomas. There 
were additional His- and Avidin- tags and also linker sequences in the provided H-AFt. This 
increases the size of H-AFt from 21 kDa to ~ 24 kDa. H-AFt was added to Gefitinib solution 
with 40-fold excess of drug, and was stirred overnight at 4°C. The un-encapsulated Gefitinib 
was removed by dialysis in 20 mM Tris (pH 8.0) using a dialysis membrane (cut-off 8 kDa) 
for 48 h at 4°C. Any impurities were removed by centrifugation (13,000 rpm, 12 min, 4°C). 
The protein concentration of H-AFt was determined by Bradford assay.40 The morphology 
was examined by transmission electron microscopy (TEM), (JEOL 2100F at 200 kV). For 
SDS-Polyacrylamide gel electrophoresis (PAGE), following denaturation (T = 95 °C for 5 
min), -AFt, H-AFt-encapsulated-Gefitinib and 5 µl of molecular marker (Thermo 
Scientific) were loaded onto a 4% stacking gel and resolved in a 12% resolving gel; samples 
were separated at 100 V for 2.5 h. The gel was stained overnight with 0.5% coomassie blue, 
followed by de-staining with 50% methanol and 10% acetic acid, and imaged in an UVP 
BioDoc-It system. 
Determining encapsulation efficiency (EE): Absorbance of serial dilutions of Gefitinib (from 
sing Perkin Elmer Lambda 25 UV/VIS 
Spectrometer and WinLab ver 6.0.4.0738 and the Beer-Lambert law was used to quantify the 
encapsulated drug. The EE was estimated as a ratio between the concentration of the 
encapsulated drug and that used in synthesis.  
Confirmation of encapsulation of Gefitinib in H-AFt: H-AFt-encapsulated-Gefitinib solution 
was analysed using an Astrios EQ flow cytometer (Beckman Coulter, Summit 6.2.3.1561) 
equipped with 488 nm and 355 nm lasers. Fluorescence emission was collected using a 
405/30 band-pass filter. 
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Mass spectrometry: For matrix assisted laser desorption ionisation mass spectrometry 
(MALDI), H-AFt-encapsulated-Gefitinib as 
the resulting solution was loaded onto a MALDI target sample plate. The plate was left to air 
dry for 5 min and was analysed on the Bruker Ultraflex III spectrometer. 
Cell lines and cell culture: SKBR3 and MDA-MB-231 breast cancer cell lines (European 
Collection of Cell Cultures) were maintained in RPMI 1640 medium supplemented with 10% 
foetal bovine serum (FBS) at 37°C in a humidified atmosphere containing 5% CO2. 
MTT assay: Cells were seeded in 96 well plates (2.5 x 103 per well) 24 h before treatment 
with Gefitinib, H-AFt-encapsulated-Gefitinib and H-AFt. Following 72 h or 120 h exposure, 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; 400 g/ml) was added 
and plates were incubated for 2.5 h. Well supernatants were aspirated and formazan 
solubilised with 150 l 100% DMSO. Absorbance at 550 nm was read on Perkin Elmer plate 
reader. 1 M HCl was introduced into medium drop-wise for MTT assays at pH 7.0. 
Clonogenic assay: SKBR3 cells (250 per well) were seeded into 6 well plates and allowed 24 
h to attach. Following 24 h treatment with Gefitinib and H-AFt-encapsulated-Gefitinib 
in half of the wells test agent was replaced with 2 ml of fresh medium. Cells in the 
remaining wells were exposed to test agents for 14 d. Experiments were terminated when 
colonies of  50 cells were formed in control wells. Colonies were washed (PBS), fixed 
(methanol; 15 min), stained (0.5% methylene blue; 15 min) and counted. Survival fractions 
(SF) were calculated: SF = Plating efficiency of treated sample / Plating efficiency of control 
x 100 %.37 
Release of Gefitinib from H-AFt: Dialysis bags (cut-off 8 kDa) containing H-AFt-
encapsulated-Gefitinib 
were placed in separate beakers containing 20 mM Tris buffer at pH 2, 4 or 7.5 at 37°C, 
5% CO2. Released Gefitinib was quantified after 2, 6, 12 and 24 h by UV spectrophotometry 
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at 250 nm. Gefitinib in the residual buffer within the dialysis bags was detected by Astrios EQ 
flow cytometry.  
Cellular uptake studies: For confocal microscopy, SKBR3 and MDA-MB-231 (2 x 104) cells 
were seeded into 8 well coverslips and allowed to attach overnight. Following 24 h exposures 
with Gefitinib or H-AFt-encapsulated-Gefitinib (5 µM), live imaging of cells was carried out 
using a Zeiss LSM 510 fluorescence microscope equipped with a UV laser of 351 nm 
excitation and LP385 emission filter. For flow cytometry studies, SKBR3 and MDA-MB-231 
cells (2.5 x 105) were seeded in 6 well plates and allowed to attach overnight before 24 h 
exposure to Gefitinib or H-AFt-encapsulated-Gefitinib (5 M). Cells were washed and 
collected into FACS tubes. Using an Astrios EQ flow cytometer, 20,000 events were acquired 
and Gefitinib fluorescence was collected.  
Statistical analyses: 
means ± SD (Standard Deviation) or ± SE (Standard Error). Significant differences were 
defined as P < 0.05. 
 
Supporting Information 
Supporting Information is available from the Wiley Online Library. 
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Figure 1. (a) Schematic representation of preparation of H-AFt-encapsulated-Gefitinib encapsulated NPs. (b) PAGE- (1) Marker (2) H-AFt (3) H-AFt-encapsulated-Gefitinib. (c) TEM Images of H-AFt/Gefitinib confirming the size of the NPs. (d) Mean fluorescence uptake by SKBR3 and MDA-MB-231 cells using flow cytometry. Mean and SD of 3 independent trials (n = 2 per trial).    
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                   Figure 2. Confocal microscopy images of SKBR3 cells demonstrating cellular uptake of Gefitinib after 24 h exposure of cells to: (a) control, (b) H-AFt, (c) Gefitinib, (d) H-AFt-encapsulated-Gefitinib. Representative images of 3 independent trials are shown (n = 2 per trial).  
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Figure 3. Representative growth inhibitory curves for Gefitinib, H-AFt and H-AFt-encapsulated-Gefitinib. MDA-MB-231 The concentration of for the H-AFt only sample is normalised to the concentration of AFt in H-AFt-encapsulated-Gefitinib. (a, c) and SKBR3 (b, d) cells were seeded at a density of 2.5 x 10 3 in 96 well plates at pH 7.5. Following 72 h (a, b) or 120 h (c, d) exposure to test agents, cell growth and viability were determined by MTT assays. Mean and SD of representative experiments of  3 independent trials are shown (n = 8 per trial).    
 1  2  3  4  5  6  7  8  9 1011121314151617181920212223242526272829303132333435363738394041424344454647484950515253545556575859606162636465
20  
0 1 2 3 4 5
0
20
40
60
80
100
0 1 2 3 4 5
 1 day 14 days 
HAFt/Gefitinib
Concentration ( M)
Gefitinib
 1 day 14 days
a) 
b) 
1 day 14 days Control 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. (a) Photographs of SKBR3 colonies following treatment of cells with 5 µM H-AFt-encapsulated-Gefitinib. (b) Effect of Gefitinib and H-AFt-encapsulated-Gefitinib treatment on SKBR3 colony formation. Cells were exposed to drug for 14 days continuously or for 24 h only (1 day) followed by 13 days in medium alone. Mean and SD of 3 independent trials (n = 3 per trial).   
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Table 1. Effect of Gefitinib,  H-AFt-encapsulated-Gefitinib and H-AFt on growth of SKBR3 and MDA-MB-231 cells. It should be noted that the GI50 values for H-AFt-encapsulated-Gefitinib refer to encapsulated Gefitinib concentration; the amount of Gefitinib encapsulated per H-AFt cage impacts material potency and merits futher detailed studies.    Mean GI50 value ± SE (µM)  Gefitinib H-AFt-encapsulated-Gefitinib H-AFt Cell line 72 h 120 h 72 h 120 h 72 h 120 h SKBR3 0.94 ± 0.49 1.66 ± 0.79 1.44 ± 0.49 0.52 ± 0.17 4.84 ± 4.80 5.50 ± 3.81 MDA-MB-231 21.80 ± 0.52 19.56 ± 0.64 >25 >25 16.47 ± 0.98 19.85 ± 0.15  
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The table of content  Anti-cancer drug Gefitinib encapsulated within human heavy chain apoferritin by diffusion; allows pH controlled sustained release of cargo. The combination of increased cellular uptake, and potent and enhanced anti-tumour activity against the HER2 over-expressing SKBR3 cell line compared to Gefitinib alone, makes it a promising carrier for delivery of drugs to tumour sites.  Keyword Apoferritin-Gefitinib  A. I. Kuruppu, L. Zhang, H. Collins, L. Turyanska, N. R. Thomas and T. D. Bradshaw   An apoferritin based drug delivery system for the tyrosine kinase inhibitor-Gefitinib  
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Supporting Information  An apoferritin based drug delivery system for the tyrosine kinase inhibitor-Gefitinib 
Anchala I. Kuruppu, Lei Zhang, Hilary Collins, Lyudmila Turyanska, Neil R. Thomas and 
Tracey D. Bradshaw* 
 
S1 Probing encapsulation by flow cytometry and MALDI. 
As Gefitinib is fluorescent under UV, H-AFt-encapsulated-Gefitinib was observed 
using excitation and emission wavelengths of 355 and 385 nm respectively by the 
405/30 band pass filter of the Astrios EQ flow cytometer. Fluorescence was detected 
by the forward scatter (FSC) and a marker was placed to detect the populations 
positive (R3) and negative (R4) for fluorescence. Figure S1.1 a shows a histogram of 
H-AFt, in which Gefitinib was not encapsulated, thus showing only a negative 
population on to the left with very little fluorescence. However after encapsulation of 
Gefitinib within the H-AFt cavity, a large positive population denoted by a 
fluorescence shift to the right was detected with a fluorescence population 180-times 
brighter than H-AFt alone (Figure S1.1 b). These data confirm encapsulation of 
Gefitinib within AFt cage. 
             
Figure S1.1. Flow cytometry histograms confirming the encapsulation of Gefitinib in H-AFt. a) H-AFt only and b) H-AFt-encapsulated-Gefitinib. 
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Matrix-enriched laser desorption ionisation (MALDI) studies revealed high intensity 
peaks (Figure S1.2) for H-AFt and Gefitinib which indicates high abundance of the 
drug and the protein in the mixture corresponding to a H-AFt molecular weight (MW) 
of 24.71 kDa and Gefitinib MW of 442.6 Da, comparable to the expected values. 
X1051.5
1.0
0.5
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442.6
24711.9
Mass to charge ratio (m/z)   Figure S1.2. MALDI spectrum of H-Aft encapsupated Gefitinib 
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S2 Cellular uptake of MDA-MB-231 cells by confocal microscopy. 
MDA-MB-231 cells (2 x 104) were seeded into 8 well chambered coverslips and allowed to 
or H-AFt-encapsulated-
Gefitinib. After 24 h, live imaging of cells was carried out using a fluorescence confocal 
microscope. Cell H-AFt-encapsulated-Gefitinib (Figure S2 c) did not 
show bright fluorescence compared to those exposed to Gefitinib (Figure S2 b).  
 
              Figure S2. Confocal microscopy images of MDA-MB-231 cells demonstrating  cellular uptake of Gefitinib after 24 h exposure of cells to: (a) control, (b) Gefitinib (c) H-AFt-encapsulated-Gefitinib. Representative images of 3 independent trials (n = 2 per trial).        
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S3 H-AFt-encapsulated-Gefitinib induced growth inhibition. 
Tumour microenvironments exhibit lower extracellular pH than normal tissues while the 
intracellular pH of cells within normal and tumour cells is similar.36 This acidic enviornment 
may help to relase the encapsulated cargo. Hence it was tested whether a more acidic in vitro 
environment would promote effective release of Gefitinib from H-AFt cage (Figure S3). 
Lower GI50 values were observed at pH 7.0 following 72 h exposure compared to normal pH 
(pH 7.5) conditions for H-AFt-encapsulated-Gefitinib (GI50 = 0.44 ±  0.16 µM). Gefitnib also 
showed low GI50 values at pH = 7.0 (GI50 = 0.13  ±  0.06 µM). 
  
 
 
 
 
 
 
 
Figure S3. Representative growth inhibitory curves for H-AFt-encapsulated-Gefitinib and Gefitinib. SKBR3 cells were seeded at a density of 2.5 x 10 3 in 96 well plates at pH 7.0. Cells were treated after 24 h and exposed to agent for 72 h. Mean and SD of representative experiments (n = 8 per trial). 
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S4 pH induced drug release. 
H-AFt cage is pH sensitive thus allowing the control of drug release by the properties 
of the environment.5 The pH dependent reassembly property of AFt could be advantageous 
for applications in tumours where extracellular pH is lower than in normal tissues and in 
stomach cancers, where an acidic environment would enhance the drug release from the AFt 
cavity. UV spectrometry was adopted to compare Gefitinib release from H-AFt at pH 2, 4 and 
7.5. Release of Gefitinib alone was observed only at pH 7.5. By analysing the buffer which 
was released from the dialysis bags it was observed that Gefitinib showed a rapid release 
profile with a higher % of drug release. Gefitinib release reached a plateau phase at 6 h. In 
comparison at pH 2, 4 and 7.5, H-AFt-encapsulated-Gefitinib showed a slower cumulative 
release profile and a lower % of drug release due to being encapsulated in the AFt cavity. 
Among the pH levels the fastest cumulative release profile was observed for H-AFt-
encapsulated-Gefitinib at pH 2 (Figure S4 a).  
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  Figure S4. Detection of Gefitinib released from H-AFt cavity (a) Cumulative release of Gefitinib alone at pH 7.5 and from H-AFt-encapsulated-Gefitinib at pH 2, 4 and 7.5 at 2, 6, 12 and 24 h observed by UV spectrometry. (b and c) Representative histograms representing fluorescence emitted by Gefitinib. A marker was placed to detect the positive (R3) and the negative (R4) populations for fluorescence. (b) Residual H-AFt alone, (c) Residual H-AFt-encapsulated-Gefitinib (pH 7.5). Mean and SD of 3 independent trials (n = 3 per trial).   
The residual buffer with NPs remaining in the dialysis bags at all studied pH levels was 
analysed by flow cytometry and compared to H-AFt only (control), also placed in a dialysis 
bag (Figure S4 b). At pH 2 and 4, residual dialysis bag buffer revealed only 2 negative (R4) 
populations exposing no fluorescence in the histograms relative to control. However at pH 7.5, 
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a small population positive for fluorescence remained (R3): 18.0 ± 3.1 times brighter 
fluorescence was detected compared to H-AFt alone, which corroborates to the results 
obtained by UV spectrometry (Figure S4 c). 
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